{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046163","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.829985+00:00","generated_at":"2026-05-24T04:02:03.003035+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Acrivon reports Q4/FY24 net loss $22.8M/$80.6M; ACR-368 endometrial cancer cORR 35% in BM+ patients","bullets":["Cash $184.6M as of Dec 31, 2024; runway extended into 2027.","ACR-368 in BM+ endometrial cancer: 35% cORR, 80% DCR; in relapsed patients cORR 50% with mDOR >10 months.","Phase 1 ACR-2316 cleared doses 1-2; dose 3 shows tumor shrinkage; target engagement confirmed.","Endometrial cancer prioritized; ovarian and bladder deprioritized due to competition/low BM+ rate.","R&D expenses $64.0M for FY24 vs $46.0M in FY23, driven by ACR-368 and ACR-2316 clinical trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046163","json":"https://secwatch.observer/filing/0000950170-25-046163.json","markdown":"https://secwatch.observer/filing/0000950170-25-046163.md","text":"https://secwatch.observer/filing/0000950170-25-046163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025046163/0000950170-25-046163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025046163/acrv-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:02:03.003035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}